Imunon

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Imunon sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 7 completed early-phase tilt top decile by trial count

Imunon: 11 sponsored US clinical trials, 2 recruiting.

Imunon sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 3 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fallopian Tube Cancer, with 4 trials.

Top-decile sponsor footprint

Imunon ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025
RECRUITING Phase 1

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT05739981
ACTIVE NOT RECRUITING Phase 1

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT03393884
COMPLETED Phase 1

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

NCT06283459
COMPLETED Phase 1

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

NCT02480374
COMPLETED Phase 3

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

NCT02112656
COMPLETED Phase 1

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

NCT00826085
TERMINATED Phase 2

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

NCT01464593
COMPLETED Phase 3

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

NCT00617981
COMPLETED Phase 1

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

NCT00441376
COMPLETED Phase 1

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

NCT00061867

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 1
Phase 3 3

Therapeutic Areas

Fallopian Tube Cancer 4
Primary Peritoneal Cancer 3
Epithelial Ovarian Cancer 3
Hepatocellular Carcinoma 2
Ovarian Cancer 2
Primary Peritoneal Carcinoma 1

What is open in the Imunon pipeline

2 recruiting of 11 indexed (18% open); 7 completed (64%).

Phase mix: 3 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Fallopian Tube Cancer (4 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Imunon: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Imunon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share ImunonAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityInventisBio Co.Kansas State University
Imunon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Imunon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Imunon page

11 registered trials is a research-attention snapshot, not an endorsement of Imunon or any single study.

  • 2 of Imunon's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Fallopian Tube Cancer is the condition Imunon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fallopian Tube Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Imunon pipeline card: 11 registered trials from official public datasets.Report a data error.